Dual Incretin vs Triple Incretin — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, Dual Incretin and Triple Incretin represent two of the most actively transacted modalities. At Phase 2, Dual Incretin deals carry a median total deal value of $5.9B with $1.2B upfront, compared to $5.6B total value and $1.2B upfront for Triple Incretin. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Dual Incretin development milestones average $839M versus $803M for Triple Incretin. Commercial milestones are $2.8B for Dual Incretin and $2.7B for Triple Incretin. Royalty rates range from 17.4%-30% for Dual Incretin and 17.2%-30% for Triple Incretin.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Dual Incretin and Triple Incretin deal terms compare in metabolic?
Which modality commands higher royalty rates: Dual Incretin or Triple Incretin?
How do milestone structures differ between Dual Incretin and Triple Incretin?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.